InsidersTradesSigma
Track the Marinus Pharmaceuticals, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Marinus Pharmaceuticals, INC. has recorded 77 reports. Market capitalisation: €1,096.4bn. The latest transaction was reported on 11 February 2025 (Disposition). Among the most active insiders: Braunstein Scott. All data is openly available.
77
Insider Decl.
n/a
Thresholds
€5,926
1 ops.
Buy Volume
€449,616
30 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Marinus Pharmaceuticals, INC. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,491.95.
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,806 of 29,062 companies
71.3
score / 100
Value64
Quality79
FCF yld1.2%
Earn yld6.4%
EV/EBITDA8.1x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 February 2025
Declarations77 total
12,186 shares@ US$0.5514.1% of flowCommon StockSEC:0001104659-25-011243:0
5,933 shares@ US$1.101.6% of flowCommon StockSEC:0001104659-25-011239:0
Canonical exit: 12 Nov 2024 (T+90)
9,398 shares@ US$0.55100.0% of flowCommon StockSEC:0001104659-25-011238:0
8,600 shares@ US$0.5545.8% of flowCommon StockSEC:0001104659-25-011248:0
17,155 shares@ US$0.5513.9% of flowCommon StockSEC:0001104659-25-011246:0
12,707 shares@ US$0.5552.2% of flowCommon StockSEC:0001104659-25-011247:0
18,778 shares@ US$0.5516.4% of flowCommon StockSEC:0001104659-25-011240:0
5,389 shares@ US$0.5577.4% of flowCommon StockSEC:0001104659-25-011244:0
17,303 shares@ US$0.5513.7% of flowCommon StockSEC:0001104659-25-011241:0
4,600 shares@ US$0.55100.0% of flowCommon StockSEC:0001104659-25-011242:0
1,600 shares@ US$0.548.3% of flowCommon StockSEC:0001415889-25-001930:0
1,610 shares@ US$0.5422.6% of flowCommon StockSEC:0001415889-25-001928:0
4,980 shares0Common StockSEC:0001415889-24-025070:0
3,621 shares@ US$1.138.2% of flowCommon StockSEC:0001415889-24-020897:0
4,657 shares@ US$1.137.2% of flowCommon StockSEC:0001415889-24-020898:0
4,828 shares@ US$1.137.6% of flowCommon StockSEC:0001415889-24-020895:0
12,145 shares@ US$1.133.3% of flowCommon StockSEC:0001415889-24-020894:0
3,820 shares@ US$1.146.6% of flowCommon StockSEC:0001415889-24-020899:0
2,300 shares0Common StockSEC:0001415889-24-017635:0
10,918 shares0Common StockSEC:0001415889-24-017630:0
12,733 shares0Common StockSEC:0001415889-24-017629:0
2,300 shares0Common StockSEC:0001415889-24-017634:0
2,300 shares0Common StockSEC:0001415889-24-017633:0
10,918 shares0Common StockSEC:0001415889-24-017632:0
2,300 shares0Common StockSEC:0001415889-24-017639:0
25 of 77 declarations
Acerca de Marinus Pharmaceuticals, INC.
Marinus Pharmaceuticals, INC. es una empresa centrada en el desarrollo de tratamientos para trastornos neurológicos. Cotiza en el NASDAQ bajo el ticker MRNS.